|
|
Volumn 1, Issue 2, 2005, Pages 74-75
|
|
Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRHEUMATIC AGENT;
IMMUNOGLOBULIN G;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR RECEPTOR;
AGED;
ARTICLE;
BLOOD;
CARDIOVASCULAR DISEASE;
COMPARATIVE STUDY;
DRUG ANTAGONISM;
FEMALE;
FOLLOW UP;
HUMAN;
INCIDENCE;
MALE;
METABOLISM;
MIDDLE AGED;
RHEUMATOID ARTHRITIS;
RISK FACTOR;
SWEDEN;
TREATMENT OUTCOME;
AGED;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CARDIOVASCULAR DISEASES;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
IMMUNOGLOBULIN G;
INCIDENCE;
MALE;
MIDDLE AGED;
RECEPTORS, TUMOR NECROSIS FACTOR;
RISK FACTORS;
SWEDEN;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 33748993415
PISSN: 17458382
EISSN: None
Source Type: Journal
DOI: 10.1038/ncprheum0066 Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
